SCHEMBL1650240

SCHEMBL1650240

COc1cc(O)cc(/C=C(/O/C(=C/c2cc(O)cc(OC)c2)c2cccc(OC)c2)c2cccc(OC)c2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ USP2 O75604 1/20 0.49
▸ TP53 P04637 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ TRPV1 Q8NER1 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ ESR1 P03372 1/20 0.48
▸ ESR2 Q92731 1/20 0.48
▸ PTGS2 P35354 2/20 0.46
▸ TTR P02766 1/20 0.46
▸ CYP1A1 P04798 1/20 0.46
▸ ALOX5 P09917 1/20 0.46
▸ CYP1B1 Q16678 1/20 0.46
▸ CES2 O00748 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1651475 0.92 PDE4A (0.51) MEN1ALDH1A1KMT2ACES2CES1
SCHEMBL1651473 0.92 PDE4A (0.51) MEN1ALDH1A1KMT2ACES2CES1
SCHEMBL1654001 0.89 MEN1 (0.47) MEN1ALDH1A1KMT2AKDM4EUSP2
SCHEMBL1650451 0.88 MEN1 (0.59) MEN1ALDH1A1KMT2AKDM4EUSP2
SCHEMBL1650904 0.83 NQO2 (0.59) MEN1ALDH1A1KMT2AKDM4EUSP2
SCHEMBL1652049 0.81 NQO2 (0.49) MEN1ALDH1A1KMT2AKDM4EUSP2
SCHEMBL1650690 0.81 NQO2 (0.46) MEN1ALDH1A1KMT2ASMN1; SMN2ABL1
SCHEMBL1650692 0.81 NQO2 (0.46) MEN1ALDH1A1KMT2ASMN1; SMN2ABL1
SCHEMBL1650710 0.80 NQO2 (0.51) MEN1ALDH1A1KMT2AKDM4EUSP2
SCHEMBL1650706 0.80 NQO2 (0.51) MEN1ALDH1A1KMT2AKDM4EUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10112881-B2 Skin lightening compounds WISYS TECHNOLOGY FOUNDATION, INC. (US) 2018-10-30 — — US disclosed
US-20170342047-A1 Cancerous Cell Growth Inhibiting Compounds WISYS TECHNOLOGY FOUNDATION, INC. 2017-11-30 — — US disclosed
US-20170197897-A1 Skin Lightening Compounds WISYS TECH FOUND INC (US) 2017-07-13 — — US disclosed
WO-2016014529-A1 SKIN LIGHTENING COMPOUNDS WISYS TECHNOLOGY FOUNDATION, INC. (US) 2016-01-28 — — WO disclosed
US-8530512-B2 Broad spectrum gram-positive antimicrobials and anthelmintics with efficacy against drug-resistant strains and Mycobacterium species MONTE AARON P (US) 2013-09-10 — — US disclosed
US-20110092578-A1 Broad Spectrum Gram-Positive Antimicrobials and Anthelmintics with Efficacy Against Drug-Resistant Strains and Mycobacterium Species MONTE AARON P 2011-04-21 — — US disclosed
US-20070292545-A1 ANTI-INFECTIVE AGENTS AND METHODS OF USE WISYS TECHNOLOGY FOUNDATION 2007-12-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342047-A1 Cancerous Cell Growth Inhibiting Compounds TYR, MKI67, MC1R MEN1 263/4885ALDH1A1 113/4885KMT2A 1488/4885
US-10112881-B2 Skin lightening compounds TYR, MC1R, MCHR1 MEN1 1459/4885ALDH1A1 108/4885KMT2A 1981/4885
US-20110092578-A1 Broad Spectrum Gram-Positive Antimicrobials and Anthelmintics with Efficacy Against Drug-Resistant Strains and Mycobacterium Species ABCC1, H1-3, H1-2 MEN1 3549/4885ALDH1A1 990/4885KMT2A 1759/4885
US-20070292545-A1 ANTI-INFECTIVE AGENTS AND METHODS OF USE H1-3, H1-0, H1-2 MEN1 2664/4885ALDH1A1 660/4885KMT2A 1847/4885
US-20170197897-A1 Skin Lightening Compounds TYR, MC1R, MCHR1 MEN1 1398/4885ALDH1A1 64/4885KMT2A 2209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback